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Heme is an essential cofactor and signaling molecule implicated in a variety of 
diseases. For this reason, understanding how heme is transported and trafficked within 
many contexts would greatly help us in these health-related aspects. In order to better 
understand heme homeostasis, it is important to build a complete description of heme 
binding proteins. Proteomic techniques have been used to determine the heme binding 
proteome using heme affinity chromatography. One downside to this is that enrichment 
methods used often contain many non-specifically binding proteins, due to the hydrophobic 
properties of heme. To improve upon these enrichment methods, use of bioorthogonally 
labeled heme (BLH) can allow for hemoproteins bound to this BLH to be enriched from 
cells. This can enable the cell to incorporate the labeled heme in a physiologically relevant 
way. In this work, a variety of BLH were characterized and tested in Saccharomyces 
cerevisiae to prove the efficacy of this novel enrichment method. Studying these BLH both 
in vivo and in vitro has given us a better idea of how to implement them to discover 
hemoproteins in a wide range of contexts, which were previously unknown. This approach 
could greatly expand our ideas of the hemoproteome in organisms already being studied as 
well as more difficult organisms which are not genetically tractable.
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CHAPTER 1. INTRODUCTION 
1.1 Heme Functions and Biology 
Heme b (iron protoporphyrin IX) is an essential cofactor and signaling molecule that 
helps facilitate a wide range of biological processes. These functions include gas binding, 
electron transport and catalysis.1–5 Due to its utilization in such a diverse manner, heme 
can be found in virtually every compartment of the cell. Despite being essential for so many 
roles within the cell, heme is also cytotoxic due to its hydrophobicity and ability to produce 
reactive oxygen species.6,7 These facts necessitate that heme concentrations and 
bioavailability are tightly regulated.1–3,5 Misregulation of heme can be linked to diseases 
such as cardiovascular disease, neurodegenerative disease, and certain cancers.5,8–11 The 
extent of our knowledge around heme homeostasis is mainly pertaining to heme synthesis 
and the physiology around tight binding hemoproteins. Heme trafficking on the other hand 
is not well understood. 
Heme synthesis begins and ends in the mitochondria, from which it can be trafficked 
to populate a wide range of hemoproteins. This is done through a highly conserved eight-
step pathway known as the Shemin pathway. Succinyl-CoA and Glycine are first converted 
to δ-aminolevulinic acid (ALA) in the mitochondria. ALA is then trafficked to the cytosol, 
where the next four steps convert 8 equivalents of ALA to coproporphyrinogen III. 
Coproporphyrinogen III is then transported back to the mitochondria for the final three 
steps, the final step being the insertion of iron into protoporphyrin IX to form heme.12–14 
From the matrix of the mitochondria heme is then transported to the mitochondria 
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intermembrane space, cytosol, endoplasmic reticulum, and nucleus to populate the cells 
hemoproteins. 
 
Figure 1: Heme biosynthetic pathway. The biosynthesis of heme is shown to occur in both 
the cytosol and mitochondria through an eight-step pathway. Glycine and succinyl-CoA 
are converted to ALA through ALA synthase (ALAS). ALA is then trafficked out of the 
cell and converted to porphobilinogen (PBG), hydroxymethyl bilane (HMB), 
uroporphyrinogen III (UROgenIII), and finally coproporphyrinogen III (CPgenIII) through 
4 enzymatic steps involving ALA dehydratase (ALAD), PBG deaminase (PBGD), 
uroporphyrinogen III synthase (UROS), and uroporphyrinogen III decarboxylase (UROD). 
CPgenIII is then imported into the mitochondria where it is converted to protophoryrinogen 
IX (PPgen IX), protophyrin IX (PPIX) and finally heme through coproporphyrinogen III 
oxidase (CPOX), protophyrin IX oxidase (PPOX), and ferrochelatase (FECH). Mitoferrin 
(Mfrn) is involved in trafficking ferrous iron to the matrix of the mitochondria, while 2-
oxoglutarate carrier (OGC) and ATP-binding cassette B6 (ABCB6) may be involved in the 
transport of CPgenIII into the inner membrane space. Reprinted (adapted) with permission 
from Severance, S.; Hamza, I. Chem. Rev. 2009, 109(10), 4596-4616. Copyright 2009 
American Chemical Society.1 
 
 While heme biosynthesis is well understood, there is very little known about the 
transport and trafficking of heme. As shown in Figure 2, heme is trafficked to each 
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compartment through pathways that are yet to be determined. The information we do know 
has been pieced together from various eukaryotic models. To name a few, two putative 
plasma membrane localized heme importers, heme responsive gene 1 and 4 (HRG-1 and 
HRG-4), two putative heme exporters, feline leukemia virus subgroup c receptor 1a and 1b 
(FLVCR1a and FLVCR1b), which are plasma membrane and mitochondrial localized, 
have been identified.1,15 HRG-1 and its paralogue HRG-4 were first discovered in C. 
elegans through genetic screens, while only HRG-1 is found in the human genome. FLVCR 
1 and 1b were shown to export heme in various mammalian models. As for chaperones and 
heme binding proteins, only a handful have been determined, HRG-2, HRG-3, glutathione 
s-transferase, fatty acid binding protein, and glyceraldehyde phosphate dehydrogenase 
(GAPDH) to list a few which are localized to the cytosol. HRG-2 is a membrane bound 
protein which facilitates in heme utilization by extraintestinal tissue while HRG-3 has been 
studied extensively in C. elegans to show that it is excreted in order to facilitate heme 
delivery within the intestines.1,2 GAPDH has also been shown to buffer heme under various 
conditions in yeast models. 3 Many of the other putative heme chaperones have been 
determined based on their heme binding abilities, though their roles in vivo are not fully 
determined.1,2 Thus, developing tools to better understand heme trafficking is essential to 
understanding diseases in which heme homeostasis is misregulated. 
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Figure 2: Schematic of heme trafficking pathways. Arrows with question marks (?) 
indicate unknown trafficking factors and potential hemoproteins of interest, while heme is 
represented by the red crosses. Some of the known factors involved in heme trafficking are 
listed in blue: feline leukemia virus subgroup C receptor (FLVCR), breast cancer resistance 
protein (BCRP), ABCB6, and heme responsive gene 1 (HRG1). Reprinted (adapted) with 
permission from Severance, S.; Hamza, I. Chem. Rev. 2009, 109(10), 4596-4616. 
Copyright 2009 American Chemical Society.1 
 
1.2 Current Hemoprotein Discovery Methods 
Many genetic and biochemical approaches have been developed to identify protein 
and pathways involved in regulating heme homeostasis. Genetic approaches typically 
involve creating mutant cell lines by chemical mutagenesis, targeted gene deletion, or gene 
over-expression and screening mutants for heme-dependent phenotypes, including growth 
under heme deficiency or surplus, or screening the activity of heme enzymes. For example, 
observing the activity of catalase, cytochrome P450 enzymes, or heme-dependent 
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transcription factors can determine how specific mutations impact heme dependent 
processes and have the potential to reveal new heme transport and trafficking factors that 
dictate heme availability.4,16,17 However, given that heme synthesis is impacted by many 
factors, including iron, zinc, and copper homeostasis, as well as oxygen availability and 
sensing, it is often difficult to parse heme synthesis from heme trafficking using genetic 
screens. 
 Biochemical approaches towards identifying heme trafficking factors complement 
genetic approaches quite well. Most commonly, hemin-agarose affinity chromatography is 
employed to enrich hemoproteins from complex cell and tissue extracts. The enriched 
hemoproteins are then chromatographed by SDS PAGE, isoelectric focusing, and/or ion 
exchange chromatography, followed by mass spectrometry to identify novel heme binding 
proteins.18–20 Two major downsides that come with this technique are that 1) many non-
specific binders are typically pulled out of solution and 2) candidate proteins may not bind 
heme in vivo in a physiologically meaningful way. Reducing this background of non-
physiological heme proteins could help give a more meaningful list of putative 
hemoproteins that could then be characterized through more direct methods.  
The Reddi lab has pioneered new integrated genetic and biophysical approaches 
towards characterizing heme homeostasis. The lab has developed genetically encoded 
ratiometric fluorescent sensors for heme that can image and quantify bioavailable heme. 
Using these probes in combination with genetic screens, the Reddi lab is systematically 
identifying new heme homeostatic factors and physiological conditions that regulate heme 
bioavailabilty.4,5 Despite the utility of traditional genetic and biochemical approaches, and 
the development of new fluorescent probes for heme, more tools are needed to dissect heme 
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homeostasis. This work is focused on the development of new azido-heme analogs that can 
be utilized to enrich and identify novel hemoproteins in a variety of cell types. 
 
1.3 Background and Chemistry  
The development of bioorthogonal labels has been instrumental in many different 
contexts. Often times used to label substrates or metabolites, bioorthogonal labels are 
frequently used to enrich the modified proteins which have allowed the labeled substrate 
or ligand to be incorporated into the protein.21–24 In this work, a bioorthogonal label, azide, 
was attached to heme and used to enrich proteins that interact with the bioorthogonally 
labeled heme (BLH). Feeding cells BLH can allow the incorporation into proteins through 
the use of the cellular machinery. Subsequent enrichment of proteins bound to the labeled 
heme can then be done through the method described. 
 The synthesis of BLH follows a well-developed, one pot amide bond formation 
reactions. Carbodiimide reagents have been used to form an amide bond between 
carboxylates and amines.25 These reagents allow for the carboxylate to be activated, such 
that it can be attacked by the nucleophilic amine and result in the formation of an amide 
bond. The first step in Figure 3 shows how dicyclohexylcarbodiimide (DCC) can be used 
to append 3-azido-1-propanamine to one of the carboxylates of heme, catalyzed by 
hydroxybenzotriazole (HOBt). This was applied with other reagents containing differing 





Figure 3: The two chemical modifications made to heme throughout the studied method 
of hemoprotein enrichment. The first step, Amide Bond Formation, is done in a one pot 
reaction and then purified for subsequent use. The addition of dicyclohexylcarbodiimide 
under basic conditions allows for the activation of the carboxylates of heme. The addition 
of amine linked to azide then allows the amine group to form a peptide bond with the 
activated carboxylate, while catalyzed by HOBt. In the second step, the azide group is then 
able to react with phosphine linked to biotin through Staudinger ligation, a type of Click 
Chemistry. 
 
 Once appended, the bioorthogonal azide can be reacted with a phosphine reagent 
through Staudinger ligation to covalently link a functional group to it. The Staudinger 
ligation can allow for an affinity label to be added to the bioorthogonal handle and then be 
enriched.26–29 In the second step of Figure 3, the azide of the BLH is reacted with phosphine 
PEG-3 biotin covalently attaching the biotin group to heme. The biotin labeled heme can 
be pulled on with solid phase bound streptavidin. This type of affinity label is commonly 
used due to the affinity of biotin and streptavidin being the highest known noncovalent 




1.4 Overview of Enrichment Method 
To improve upon currently inefficient affinity purification methods, we use 
bioorthogonal azide labels to enrich hemoproteins from cells. The method utilized allows 
the cells to incorporate BLH through use of the cellular machinery, the steps of which are 
shown in the schematic of Figure 4. By feeding BLH, cells can uptake and incorporate 
BLH into its hemoproteins. Once lysed, Staudinger ligation appends biotin, which can then 
be enriched with solid-phase bound streptavidin. Proteins can then be eluted and analyzed 
by SDS-PAGE gel imaging and mass spectrometric approaches. The subsequent chapters 
will show how this method can be effectively implemented. 
 
Figure 4: Schematic of hemoprotein enrichment from cells using BLH. In this work flow, 
BLH are fed to cells. The cells can then be lysed and biotin appended through click 
chemistry described above. Proteins bound to the BLH can then be enriched with solid 
phase bound streptavidin. These proteins can then be eluted and further studied. 
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CHAPTER 2. SYNTHESIS AND CHARACTERIZATION 
2.1 Introduction 
In our approach of hemoprotein discovery, we used a bioorthogonal label, azide, to 
enrich heme binding proteins. Bioorthogonal labeling with azides have been effectively 
used in many different proteomic approaches, often to look at labeled substrates or 
metabolites which get incorporated into proteins.21–24 A major difference in our approach 
is that our label is not covalently incorporated into the protein. For this reason, testing how 
the modification impacts many properties in comparison to heme is essential to determine 
if bioorthogonally labeled heme (BLH) will be effective in hemoprotein enrichment. We 
also needed to try a variety of different BLH to see if differences in linker length could 
improve the properties of the BLH. With these various parameters, we were able to 
characterize each and determine which analog to use in further studies in cells. To start we 
synthesized and purified each compound and then were able to test a variety of properties 
in vitro that each BLH had. 
2.2 Synthesis and Purification of Heme Analogs 
First, we needed to append the bioorthogonal label to heme and purify it before we 
could determine the efficacy of this method. As shown in Figure 3, heme was converted to 
BLH with various linker lengths by amide bond formation at one of the carboxylates of 
heme. In designing this synthesis of the BLH, the two major considerations which led to 
the addition to the carboxylate were the fact that the carboxylates are not conjugated to the 
aromatic porphyrin of heme and the chemistry of the step is well understood.  
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In order to create these BLH, heme was reacted with azido amines with various linker 
lengths. This was done by appending the amine to the heme carboxylate as shown in the 
first step of Figure 3. In each case, DCC and HOBt were used to facilitate this reaction 
under basic conditions. DCC is known to activate the carboxylate, allowing for the amine 
to attack, while HOBt catalyzes the reaction. This was done with 3-azido-1-propanamine, 
azido-PEG3-amine, and azido-PEG6-amine to form azido-propyl-heme, azido-PEG3-
heme, and azido-PEG6-heme, our three BLH. 
To both monitor the reactions and do subsequent purification, reverse phase high 
performance liquid chromatography (HPLC) was used. Heme has a strong absorbance at 
400nm, known as the Soret band, making it easy to be observed by HPLC coupled to 
UV/vis detection. This was also true with the analogs generated through this synthesis, as 
will be shown in Chapter 2.3 Characterization of Heme Analogs. The addition of the azido 
amines was observed to change the retention time due to the change in hydrophobicity. In 
Figure 5, three major peaks formed from this reaction, though the heme peak observed at 
6.9 minutes was small due to depletion. The peak at 9.1 minutes was attributed to addition 
of a single azido amine per heme molecule, while the peak at 11.2 minutes was attributed 
to the addition of two azido amines per heme molecule. These analytes were collected 
during preparatory scale HPLC and confirmed by mass spectrometric analysis. In Figure 
6, the major peak at 816.3 Da corresponds with azido-PEG3-heme shown in Figure 3. The 
purified product shown in Figure 5 was found to be around 95% purity. Other samples 
ranged from 80-95% pure after purification, with mainly heme impurity. Further 
characterization was done using these purified products containing a single azido amine 
per heme shown in Figure 3. 
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Figure 5: The synthesis and purification of the BLH shown by HPLC. The formation of 
BLH was observed by a shift in retention time under reverse phase HPLC. Equal moles of 
heme, DCC, HOBt, and azido-PEG3-amine were reacted together. The reaction mix was 
then purified by preparatory scale HPLC. The reaction mix is shown in blue, while the 
purified product is shown in red. This shows the resulting purification of the PEG3 linked 
heme. The product caused by two azide PEG-3 amine molecules reacting with heme 





Figure 6: Electrospray mass spectrometric data of purified BLH. PEG3 linked heme was 
expected to have a mass of 816.7 Da. The peak corresponding to this mass is observed, 
showing that PEG3 linked heme was formed. 
 
2.3 Characterization of Heme Analogs 
When covalently attaching a bioorthogonal label, a large consideration is how this 
will impact the properties of the molecule. In our case, some major features of heme which 
could be impacted are the electronics of the porphyrin, the change of a negatively charged 
carboxylate to an amide, and the addition of a large group which could prevent protein 
binding. From the aspect of the bioorthogonal label, it is also important to think about the 
accessibility of the label as this can impact the ability of the analog to be enriched from 
solution. The characterization done addressed these questions and further allowed us to 
determine which to use in cell studies. 
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2.3.1 Spectral Characterization 
Does the appended azide significantly change the electronics of our proposed 
molecules? This was important to determining whether hemoproteins would still bind to 
BLH the same way as heme. Due to the fact that the carboxylate being altered is separated 
by three unconjugated carbons, we did not expect the electronic properties to change 
drastically from this modification. Despite this, there still existed other possible 
contributors that could have impacted the electronics of the BLH. From the result shown 
in Figure 7, it does not seem to change very much spectroscopically, as seen through 
UV/vis spectroscopy. The heme-like characteristics were determined for each of the azido-
heme analogs and seem to be relatively similar to heme independent of linker length. 
Though this does not mean binding may be impacted, further characterization was done to 






Figure 7: UV-visible absorbance spectra of each BLH. Similarities between each spectrum 
indicated that the addition of azide to the carboxylate of heme did not greatly impact the 
electronic of the molecules. Extinction coefficients were determined by serial dilution from 
30 uM to 5 uM in deionized water at pH 7. BLH spectra are named ‘propyl’, ‘PEG-3’, and 
‘PEG-6’ based on the linker of each molecule. 
 
2.3.2 Monitoring Click Reaction 
Once the azide was appended to heme to form BLH, it was important to test that 
the Staudinger ligation could occur under conditions compatible with cell lysates. In this 
reaction, each of the BLH were incubated with phosphine-PEG3-biotin, which is shown in 
the second step of Figure 3. Data from this reaction can be seen by HPLC chromatograms 
in Figure 8. In each chromatogram impurity heme could be seen at 7.3 minutes. Peaks 
corresponding to the BLH could be seen at 9.7, 9.5, and 9.4 minutes for each of the propyl 
(Figure 8a), PEG3 (Figure 8b), and PEG6 (Figure 8c) linked heme respectively. In Figure 
8a, the propyl linked heme was consumed as the reaction proceeds, while two peaks at 8.8 
and 9.0 minutes appear. These resulted from product of the Staudinger ligation, in which 
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biotin is added to the azide handle. In the case of PEG3 linked heme, the starting material 
was nearly completely consumed as shown in Figure 8b, while a new peak formed at 12.2 
minutes, corresponding to the Staudinger ligation product. Finally, the PEG6 linked heme 
appeared to only react under these conditions slightly, forming a small peak for the 
Staudinger product at 11.4 minutes. From these results, it appeared that the reaction 
occurred rapidly for the propyl and PEG3 linked heme. The reaction did not seem very 
efficient for the PEG6 linked heme. This could be due to a number of factors such as 
aggregation and accessibility of the azide. But this does not discount any of the analogs 





Figure 8: Monitoring Staudinger ligation reaction by HPLC.  10 uM of each BLH with 
propyl (a), PEG3 (b) or PEG6 (c) linker were incubated with 100 uM phosphine-PEG3-
biotin in PBS for 3 hr at 37⁰C. Chromatograms in red were the BLH incubated with a 10-
fold excess of phosphine-PEG3-biotin, while chromatograms in blue are unreacted BLH. 






2.3.3 Model Hemoprotein Enrichment 
Though the modifications to heme did not seem to impact the electronics of the 
conjugated porphyrin significantly, it could still impact how hemoproteins bind and 
interact. Seeing how a model hemoprotein interacts with the BLH can help us understand 
how this modification impacts binding. Thus, we tested the ability of each BLH to enrich 
the model hemoprotein myoglobin. To do this, apo myoglobin was incubated with each of 
the BLH, propyl, PEG3, and PEG6 linked heme, along with a heme control. Each were 
incubated either with or without phosphine-PEG3-biotin. Then the samples were incubated 
with streptavidin bound to magnetic beads. These were then be washed and bound proteins 
eluted. The eluted myoglobin was then run on SDS-PAGE gel. As seen in Figure 9, the 
heme control samples were unable to enrich myoglobin because they lacked the azide, and 
therefore lacked biotin. In each of the cases of BLH without phosphine-PEG3-biotin, the 
samples were also unable to enrich myoglobin. However, in the presence of phosphine-
PEG3-biotin, each BLH was able to enrich myoglobin from solution, meaning they were 
able to bind to myoglobin. The most enrichment occurred from the PEG3 linked heme, 
while very little was seen from the propyl and PEG6 linked heme. It is difficult to discern 
whether the difference is due to effectiveness of binding or efficiency of the Staudinger 
ligation. In the case of PEG6 linked heme, very little was enriched most likely because the 
Staudinger ligation was not very efficient under these conditions. Overall each BLH was 
able to enrich myoglobin to some extent but it was still difficult to tell which would 
function best in cells. This is once again due to the fact that the uptake machinery and 
hemoproteins may interact with each BLH very differently in vivo. Therefore, testing each 
 18 





Figure 9: Myoglobin enrichment from PBS solution using BLH. Relative quantities of 
myoglobin enriched from each BLH based on band intensity shown by SDS PAGE gel 
stained with Coomassie. 10 uM of each BLH was incubated with 0.2 mg/ml apo-myoglobin 
and 100 uM phosphine-PEG3-biotin for 3 hr at 37⁰C in 100 uL PBS. Samples were then 
incubated with 50 uL streptavidin mag sepharose bead slurry before washing and eluting 
bound myoglobin with SDS at 100⁰C. BLH samples used are labelled ‘propyl’, ‘PEG-3’, 




CHAPTER 3. IN CELL STUDIES OF HEME ANALOGS 
3.1 Introduction 
The ability of cells to take up bioorthogonally labelled heme (BLH) was a major 
aspect of the method we developed. For this reason, it was important to test ways to 
improve uptake and potentially improve our ability to enrich hemoproteins from cells. To 
test the feasibility of the BLH in vivo, a variety of experiments were performed to test the 
ability of cells to uptake the BLH and incorporate them into cells. Saccharomyces 
cerevisiae, baker’s yeast, was chosen due to its ease of use and easily accessible libraries 
of yeast knock out strains. One issue with using wild type yeast cells is that their ability to 
take up exogenous heme is poor.31,32 For this reason, we attempted to improve the uptake 
of our BLH in yeast through a few different methods. In each case we were able to improve 
BLH uptake. Once it was determined that the BLH could get into cells and incorporate into 
proteins, enrichment from cells fed BLH was done. 
3.2 Cellular Uptake of Heme Analogs 
Despite poor heme uptake in wild type yeast cells, there are a number of ways to 
improve heme uptake in yeast cells. The hope in this work was to both determine uptake 
of the BLH and optimize it, such that the enrichment from cells was most effective. In these 
experiments we fed various amounts of either heme or BLH and determined quantities of 
uptake by HPLC. Much of the heme or BLH found in cells was localized to the cell wall. 
In application, this heme would not be very significant to our enrichment of soluble 
proteins from cells. Thus, we looked at heme extracted from cell lysates, rather than total 
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cellular heme. To do this, we lysed cells using an aqueous solution with detergent. The 
soluble proteins were separated from the insoluble cell debris, which contained much of 
the heme and BLH. Then acid acetone was used to extract heme and BLH from the cell 
lysates. These extracts could then be run on HPLC to quantify intracellular heme and BLH. 
Under various conditions we could then determine the optimal way to feed these BLH to 
cells. 
It has been shown that heme depleted cells uptake heme better than heme replete 
cells.32 Thus, we began by testing if these conditions could also improve uptake of our 
BLH. To deplete our cells of heme, we fed wild type cells succinylacetone (SA). SA is a 
known inhibitor of ALA dehydrogenase which is the second step in heme biosynthesis, as 
seen in Figure 1. In Figure 10a, it is seen in the blue trace that no detectable heme is 
produced by yeast under SA treatment, while those grown normally produce a small 
amount of heme, as seen by the peak at 7.8 minutes. From Figure 10b, it shows that more 
heme is found under SA treatment than without SA treatment. This corroborates the point 





Figure 10: Heme uptake under heme depleted and heme replete conditions shown by 
HPLC. Heme fed to yeast cells was extracted from soluble lysates with acid acetone (5 mM 
HCl). Yeast cells were grown up in the heme biosynthetic inhibitor succinyl acetone (SA) 
overnight prior to feeding. Yeast cells were fed 0 uM heme (a) and 25 uM (b), either under 
heme deplete conditions fed 500 uM SA (blue) or under heme replete conditions without 
SA (red). 
 
While testing BLH uptake with yeast cells under heme deplete conditions, we 
noticed slightly increased uptake in BLH, for the PEG3 and PEG6 linked heme. However, 
these increases were not very significant. This was seen from the chromatograms in Figure 
11b and 11c by the slight increase from red to blue, representing the change in BLH from 
heme replete to heme deplete cells respectively. For the PEG3 and PEG6 linked heme this 
was seen by the peaks both around 9.8 minutes. As for the propyl linked heme, the amount 
of observed BLH decreased when cells were heme depleted. This was seen in Figure 11a 
by the peak at 10.2 minutes representing the propyl linked heme. In each case the heme 
peak around 7.8 minutes also decreases under SA treatment. This was expected, though 
some residual heme is still able to be taken up due to heme impurity in the BLH samples. 
This result could indicate whether our BLH interact with yeast’s heme uptake systems 
similar to heme. Because the PEG3 and PEG6 linked heme uptake is increased while propyl 
linked heme is decreased, PEG3 and PEG6 linked heme may act more like heme than 
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propyl linked heme. Though in all cases, the difference was not as drastic as seen by heme, 
indicating that none interacted very well with the cell’s endogenous uptake systems. 
 
Figure 11: BLH uptake under heme deplete and replete conditions. Similar to Figure 10, 
yeast cells were fed BLH under heme deplete or heme replete conditions. Yeast cells were 
fed 25 uM BLH with either propyl (a), PEG3 (b), or PEG6 (c) linker. Yeast cells were fed 
BLH under heme deplete conditions, fed 500 uM SA (blue) or heme replete conditions, 
without SA (red). 
 
 Due to the fact that BLH uptake was not drastically improved under heme deplete 
conditions, we then used the over expression of a known heme uptake protein, HRG-4, to 
improve uptake of our BLH. This protein was discovered in Caenorhabditis elegans and 
shown to improve heme uptake when reconstituted in yeast.15 This method helped in two 
ways 1) We were able to see how our BLH functioned with another known hemoprotein 
and 2) We were able to improve uptake of our BLH for the purposes of our enrichment 
method. To determine these aspects, we compared yeast cells expressing HRG-4 with 
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empty vector (EV) cells, fed with heme or our BLH. Heme uptake was clearly improved 
upon HRG-4 expression, as seen in Figure 12a, as intracellular heme was increased 
between EV and HRG-4 expressing cells. In Figure 12b, uptake of the propyl linked heme 
did not change significantly, indicating that it did not function well with HRG-4. In the 
traces in Figure 12b, the propyl linked heme peaks seemed unaffected by the expression of 
HRG-4, seen by the peak at 10.0 minutes. Finally, the uptake of PEG3 and PEG6 linked 
heme in Figures 12c and 12d could be seen increasing. This was based on the fact that the 
peaks at around 9.3 minutes and 9.7 minutes increased drastically upon HRG-4 expression. 
This indicated that both PEG3 and PEG6 linked heme can be taken into the cell by HRG-
4. It also showed that this could be an effective method to improve uptake for the 





Figure 12: BLH uptake in HRG-4 expressing yeast cells. Chromatograms show heme and 
BLH extracted from cells lysates of yeast cells with or without HRG-4 expression. Yeast 
cells were fed 10 uM heme (a) or 10 uM BLH with propyl (b), PEG3 (c), or PEG6 (d) 
linker. Yeast cells containing an EV plasmid, lacking HRG-4, shown in blue, while those 
expressing HRG-4 shown in red. Both EV and HRG-4 expressing cells are grown in 0.1% 
galactose, causing induction of the galactose inducible promoter. 
 
3.3 Enrichment from Cells 
Once uptake of the BLH was well established, enrichment of proteins from cells was 
feasible. A major goal was to get as much enrichment as possible from cell while limiting 
background protein from non-specific binding. The more we could do this, the easier it 
would be to identify heme binding proteins. To achieve this, we needed to optimize various 
aspects of enrichment process. A large aspect of this was removing background caused 
from using streptavidin bound beads. 
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3.3.1 Optimization of Enrichment 
The issue of background protein binding came about because of our use of 
streptavidin bound agarose covered magnetic beads. This was due to both the proteins 
which bound to agarose and proteins which were endogenously biotinylated. These 
proteins bound independent upon treatment with BLH and phosphine biotin, which 
prevented us from getting a clear view of protein enrichment. By 1-D SDS PAGE gel it 
was especially difficult to discern some background from proteins that were enriched. 
To eliminate these background binding proteins, we used different methods of 
blocking background proteins. This included both a blocking step for endogenously 
biotinylated proteins and a preclearance step which removed sepharose binding proteins. 
To block endogenously biotinylated proteins, we added streptavidin to cell lysates. In order 
to determine the amount of streptavidin needed to block endogenously biotinylated 
proteins, we incubated lysates with varying amounts of streptavidin. Then the lysates were 
incubated with the streptavidin magnetic sepharose beads and eluted by boiling the beads. 
As seen in Figure 13, most background bands are still present after treatment with 
streptavidin, while two high molecular weight proteins are removed with increasing 
amounts of streptavidin. This is demonstrated even further when imaged by western 
blotting for biotin. This can be seen in Figure 14, as the two prominent endogenously 




Figure 13: Streptavidin blocking shown by 1-D protein gel. 360 uL of 1 mg/mL yeast 
lysates were incubated with either 0, 50, 100, or 200 ug streptavidin before incubation with 
50 uL of streptavidin magnetic sepharose bead slurry. Beads were then washed, and 
proteins eluted by SDS at 100⁰C. Eluents from the beads were then run on SDS PAGE and 
stained with Coomassie.  
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Figure 14: Streptavidin blocking shown by western blot with biotin anti-bodies. The same 
eluents from Figure 13 were run on SDS PAGE and then transferred to nitrocellulose 
membranes from western blotting. Membranes were blotted using biotin anti-bodies. 
Bands show two endogenously biotinylated proteins around 245kDa and 135kDa, which 
disappear upon streptavidin treatment. 
 
Next, cell lysates were incubated with agarose beads to attempt to remove agarose binding 
proteins. Though this step may be important to the work flow of this method, no noticeable 
difference was observed by 1-D gel in yeast cell lysates. This step is more important to 
mass spectrometry based approaches. 
 Another issue that occurred while using the streptavidin magnetic beads was that 
incubation time with the lysate impacted background greatly. It was important to allow the 
biotinylated molecules to associate with streptavidin. However, we found that process 
occurred quite rapidly. When incubation time increased, more background proteins were 
observed in elutions. As seen in Figure 15a, the number of bands increased greatly after 30 
minutes of incubation. The number of endogenously biotinylated proteins stayed constant 
through, observed in Figure 15b by using western blotting anti-biotin. This indicated the 
increasing number of bands came from non-specific binding. In order to eliminate these 
non-specifically binding proteins, incubation time was clearly important and was be 
optimized to still allow biotinylated molecules to associate. 
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Figure 15: Determining incubation times with streptavidin magnetic beads. Wild type 
yeast cell lysates (360 uL, 1 mg/mL) were incubated with 50 uL of streptavidin magnetic 
sepharose bead slurry. This was done to determine non-specifically protein binding over 
time as well as time needed to associate biotinylated proteins. Beads were washed and 
eluted with SDS at 100⁰C. Eluents are either run on SDS PAGE gel and stained with 
Coomassie to show all proteins bound (a) or by western blotting with anti-biotin to show 
biotinylated proteins associated specifically to streptavidin (b). 
 
 When boiling the streptavidin magnetic beads to elute proteins, proteins bound to 
the beads may elute even though they are not associated with our BLH. This is because use 
of SDS and boiling the samples causes all proteins bound to the protein to become 
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solubilized. To try to selectively elute proteins bound to our BLH, we tried to add an excess 
of imidazole. This method allows for the imidazole to exchange with the ligands binding 
to the iron of the BLH, causing the protein initially associated to dissociate. This was done 
to elute myoglobin enriched from solution. Either heme or our BLH analog was incubated 
with myoglobin and then reacted with phosphine-PEG3-biotin. This solution was then 
incubated with the streptavidin magnetic sepharose beads. The beads were washed and then 
the myoglobin bound was eluted either by boiling is SDS or with imidazole at various 
temperatures. As seen in Figure 16, each sample incubated with heme was unable to enrich 
myoglobin because it lacked the ability to bind the streptavidin magnetic beads. In each 
case with the BLH analog myoglobin could be seen to elute. This meant that eluting a 
model hemoprotein was effective by using an imidazole elution or boiling in SDS. 
 
Figure 16: Comparing elution conditions from streptavidin magnetic beads with 
myoglobin enrichment. 0.2 mg/mL apo-myoglobin was incubated with 10 uM of either 
heme (H) or PEG3 linked heme analog (A) in 100 uL PBS. Then 100 uM phosphine-PEG3-
biotin was reacted with both followed by incubation with 50 uL of streptavidin magnetic 
sepharose bead slurry. Bound myoglobin was then eluted with equal volumes of SDS at 






3.3.2 Applications of Method 
Once we had developed the method of feeding BLH and the method of hemoprotein 
enrichment from solution, we wanted to apply it in order to enrichment hemoproteins from 
cells. Enrichment was observed by 1-D SDS PAGE with relative ease. Though 1-D SDS 
PAGE has been effective in showing that enrichment with the BLH is possible, use of 
quantitative mass spectrometry would greatly improve this result. With this method, 
protein identification and enrichment would be determinable. From that list of proteins 
collected, we could then study those proteins further. 
First, we wanted to know which BLH worked best at enriching proteins from cells. 
To do this heme deplete wild type yeast cells were fed as described above. The blocked 
and precleared lysates were then split and either treated with or without phosphine-PEG3-
biotin. They were then incubated with streptavidin magnetic sepharose beads. Proteins 
bound were then eluted and run on 1-D SDS PAGE. As seen in Figure 17, background can 
still be seen in lanes lacking phosphine-PEG3-biotin. But in each case, the addition of 
phosphine-PEG3-biotin led to a darkening of the lane as well as specific bands darkening. 
This implies that each of BLH are able to enrich proteins from lysate, though there is still 
significant background visible. When comparing between BLH, it appears that the PEG3 
and PEG6 linked heme is able to enrich more protein from lysates than the propyl linked 
heme. The fact that the propyl linked heme does not seem to enrich proteins as well is 
consistent with our in vitro characterization.  
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Figure 17: Proteins enriched from yeast cells fed BLH with either propyl, PEG3, or PEG6 
linker. Wild type yeast cells grown up under heme deplete conditions with 500 uM succinyl 
acetone were fed 25 uM of each BLH. The cell lysates (360 uL, 1 mg/mL) were either 
incubated without (-) or with (+) 200 uM phosphine-PEG3-biotin and then enriched with 
50 uL of streptavidin magnetic sepharose bead slurry. Beads were washed and eluted with 
an imidazole elution buffer. Eluents were then run on SDS PAGE and then stained with 
Sypro ruby protein stain. 
 
 Once determined that we could enrich proteins to some extent from wild type cells, 
we also wanted to try under the condition of HRG-4 over expression to improve BLH 
uptake. In this experiment, we fed HRG-4 expressing cells either heme or BLH. This way 
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BLH could be reacted with phosphine-PEG3-biotin while heme could not be. The similar 
blocking and preclearance steps were taken to remove background. In this case both lysates 
were reacted with phosphine-PEG3-biotin and then incubated with streptavidin magnetic 
sepharose beads. The eluted proteins can be seen in Figure 18. Under the lane for cells fed 
heme, the background binding proteins can be seen, as heme cannot react with phosphine-
PEG3-biotin and can therefore not enrich proteins bound. As for those fed with PEG3 
linked heme, similar background can be seen plus the addition of a few bands. This result 





Figure 18: Proteins were enriched from cells expressing HRG-4 using BLH. Yeast cells 
were fed 25 uM of either heme (H) or PEG3 linked heme analog (A). Both lysates were 
reacted with 200 uM phosphine-PEG3-biotin and then enriched with 50 uL streptavidin 
magnetic bead slurry. Beads were washed and eluted into SDS at 100⁰C. Eluents were run 
on SDS PAGE and stained with Sypro ruby protein stain. Arrows indicate proteins visibly 
enriched in PEG3 linked heme samples compared to heme samples. 
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CHAPTER 4. CONCLUSION AND FUTURE WORK 
4.1 Conclusion and Future Work 
Heme is an important cofactor found everywhere within the cell, essential to virtually 
every aerobic organism. Despite being ubiquitous, little is known about heme trafficking 
and homeostatic factors. In order to build a better picture of these aspects of heme, we have 
designed a tool that can help in the determination of heme binding proteins. Through the 
use of bioorthogonal azide labeling, we were able to modify heme in a way that did not 
significantly impact the electronics of heme or its ability to bind model hemoproteins. We 
were also able to show that some of the bioorthogonally labelled heme (BLH) were able to 
act in a heme-like way with known hemoproteins, such as myoglobin and HRG-4. After 
optimizing uptake of the BLH and the method of enrichment, we were able to see 
enrichment of some proteins from cells fed BLH.  
In many cases this enrichment was not significantly greater the protein background 
from using streptavidin magnetic beads, observed by 1-D gel. This is a portion of the work 
that still requires improvement in order to implement it. We believe that little enrichment 
compared to the background observed could be due to many factors including limitations 
to the click reaction, proteins dissociating from BLH under reaction conditions, and simply 
low hemoprotein abundance. To successfully implement this method, further optimization 
of the click reaction conditions would be necessary along with limiting background binding 
proteins further. Once this is done mass spectrometric analysis could be done to identify 
proteins enriched through this method. The proteins identified could then further be studied 
to determine their impact upon heme homeostasis. 
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Once this method is optimized to effectively enrich known and novel hemoproteins 
from cells, it could be extended to study the heme binding proteome in a variety of different 
genetically intractable organisms. Many pathogens contain heme uptake systems which 
could be further studied using these methods of hemoprotein enrichment. A few examples 
of model organisms that this method could be applied in would be Candida albicans and 
Mycobacterium tuberculosis, in which heme uptake has already been characterized to some 
extent.33,34 The use of our BLH could improve our understanding of heme homeostasis in 
these contexts as well.  
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APPENDIX A. METHODS 
Table 1: Description of plasmids used 
Plasmids Used Description 
pRS316-GAL-EV Empty vector plasmid with gal inducible 
promoter under ura selection 
pYes-Dest52-HRG4 HRG4 expressing plasmid with gal inducible 
promoter under ura selection 
 
Reagents and Materials Used. N,N’-dicyclohexylcarbodiimide (DCC, 99%) was 
acquired from Alfa Aesar Cas #  538-75-0, 1-hydroxybenzotriazole hydrate wetted with 
not less than 20% water (HOBt, 97%) was acquired from Chem Impex International Inc 
Cas # 123333-53-9, 3-azidopropylamine (>95%) was acquired from Tokyo Chemical 
Industry Cas # 88192-19-2, 11-azido-3,6,9-trioxaundecan-1-amine (azido-PEG3-amine, 
>95%) was acquired from Tokyo Chemical Industry Cas # 134179-38-7, O-(2-
Aminoethyl)-O′-(2-azidoethyl) pentaethylene glycol (azido-PEG6-amine, >90% oligomer 
purity) was acquired from Sigma Aldrich Cas # 957486-82-7, myoglobin from equine 
skeletal muscle (95-100%) was obtained from Sigma Aldrich Cas # 100684-32-0, 
streptavidin was acquired from VWR  Cas # 97062-810, EZ-link™ phosphine-PEG3-
biotin was acquired from Thermo Scientific Cat # 88901, sepharose® 4B (sepharose bead 
slurry) was acquired from Sigma Aldrich Cas # 9012-36-6, PD SpinTrap™ G-25 was 
acquired from GE Healthcare Cat #28918004, Streptavidin Mag Sepharose™ was acquired 
from GE Healthcare Cat # 28985799 
Synthesis of Heme Analogs. A solution of hemin-cl (13 mg, 2 mmoles, 1 eq) in dimethyl 
formamide with 5% pyridine (2 mL, 10 mM) was prepared followed by the addition of 
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DCC (4 mg, 2 mmoles, 1 eq) and HOBt (3 mg, 2 mmoles, 1 eq) in a 15 mL centrifuge tube. 
Either 3-azido-1-propanmine (2 uL, 2 mmoles, 1 eq), azido-PEG3-amine (4.36 uL, 2 
mmoles, 1 eq), or azido-PEG6-amine (7 uL, 2 mmoles, 1 eq) was added and left to agitate 
on nutating mixer for 48-72 hours covered in aluminum foil at room temperature. Reaction 
progress was checked by analytical scale HPLC described below.  
Preparatory HPLC Purification. The reaction mix was diluted 1:5 in 50% 
acetonitrile/50% water with 0.1% trifluoroacetic acid. 5 mL was then run on C3 preparatory 
scale HPLC. The mobile phase was run on a gradient from 50-52.5% acetonitrile with 0.1% 
trifluoroacetic acid over 30 minutes at 5 mL/minute, followed by sustained 52.5% 
acetonitrile with 0.1% trifluoroacetic acid at 5mL/minute for 15 minutes. The column was 
then washed for 20-30 minutes with 100% acetonitrile. Chromatograms were monitored at 
400 nm, 280 nm, and 220 nm. Fractions were collected every two minutes. Fractions were 
analyzed by analytical scale HPLC described below. Significant fractions were then 
lyophilized and resuspended in DMSO. Heme eluted 19-21 minutes, PEG3 linked heme 
eluted 22-25 minutes, and 2x(PEG3-azide) linked heme eluted 26-29 minutes. 
Analytical HPLC Analysis. Samples were diluted into 50% acetonitrile/50% water with 
0.1% trifluoroacetic acid. 20 uL of the diluted sample was then run on C18 analytical scale 
HPLC. The mobile phase was run on a gradient from 40-55% acetonitrile with 0.1% 
trifluoroacetic acid, over 15 minutes, at 1 mL/minute. The column was then washed for 10 
minutes with 100% acetonitrile. Chromatograms were monitored at 400 nm, 280 nm, and 
220 nm. 
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Yeast Strains, Genetic Manipulations, and Media. S. cerevisiae strains used were 
derived from BY4741. Yeast transformations were done following a lithium acetate 
procedure.35 Strains were grown at 30⁰C on synthetic complete media (SC) supplemented 
with glucose. Heme deplete cells were grown on SC media with 500 uM SA. Strains 
containing plasmids with galactose inducible promoters were grown with SC media drop 
out media without uracil to maintain selection, supplemented with 2% raffinose and 0.1% 
galactose. 
Apo-myoglobin Preparation. Apo-myoglobin stocks were made extracting heme from 
myoglobin. 5 mL of 15-20 mg/mL myoglobin in deionized water was added dropwise to 
250 mL acid acetone (5 mM HCl) at 4⁰C in a 250 mL flask. The suspension was then 
centrifuged at 3200 g at 4⁰C for 10 minutes and supernatant removed. If the pellet was still 
red, then it was resuspended in 50 mL fresh acid acetone at 4⁰C followed by centrifugation 
at 3200 g and removal of supernatant. The final precipitate was then resuspended in 4 mL 
cold deionized water and dialyzed at 4⁰C in 500 mL 1xPBS at pH 7.4. Precipitate was then 
pelleted, and supernatant was used for subsequent experiments.36  
Myoglobin Enrichment Conditions. In 100 uL of 1x PBS, apo-myoglobin stocks (19.6 
mg/mL in PBS) were diluted to 0.2 mg/mL. Heme or BLH (10 mM in DMSO) was added 
to a final concentration of 10 uM. Then phosphine-PEG3-biotin (10 mM in DMSO) was 
added to a final concentration of 100 uM. Samples were then incubated at 37⁰C for 3 hours. 
50 uL of streptavidin magnetic sepharose bead slurry were equilibrated with 200-300 uL 
of lysis buffer. The myoglobin/BLH solution was then added to 50 uL streptavidin 
magnetic sepharose bead slurry and left at room temperature agitating on nutating mixer 
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for 30 minutes. Solution was removed, and beads were washed 3 times with 750 uL of 
1xPBS for 5 minutes per wash. Samples were eluted into 50 uL of 1x SDS (5x SDS that 
was diluted into PBS) by heating to 100⁰C for 10 minutes. In some cases, an imidazole 
elution was done by adding 50 uL of 1 M imidazole in lysis buffer (10mM NaPi, 50mM 
NaCl, 5mM EDTA, 0.1% Triton x-100, pH 7.4 after imidazole addition) and incubating 
for 15 minutes at room temperature. 5x SDS was then added to imidazole eluted samples 
and denatured at 100⁰C for 5 minutes. Eluents were then run on SDS PAGE and stained 
with Coomassie. 
Determination of Heme and BLH Uptake. Cells were grown overnight at 30⁰C to around 
1 OD/mL. The cells were then pelleted and reinoculated at 10 OD/mL in 1.5 mL fresh 
media with 10- 25 uM of heme or BLH for 3 hours. Cells were then pelleted in a 1.5 mL 
centrifuge tube. Cell pellets were washed with washing buffer (0.1% tween 20, 2% bovine 
serum albumin in 2x PBS). They were then lysed into 50 uL lysis buffer (10mM NaPi, 
50mM NaCl, 5mM EDTA, 0.1% Triton x-100, pH 7.4) with about 1 pellet volume of ZrO 
beads using a bullet blender, at speed 8 for 3 minutes. Cell debris was removed by 
centrifugation and lysates collected. Heme and BLH were then extracted from lysates by 
adding cell lysates dropwise to cold acid acetone (5 mM HCL). Protein precipitates were 
then pelleted by centrifuging at 14.0 G for 3 minutes. Extracts were then run on analytical 
scale HPLC described above. 
Enrichment from Yeast Cell Lysates. Cells were grown overnight at 30⁰C to around 1 
OD/mL. The cells were then pelleted and reinoculated at 10 OD/mL in 1.5 mL fresh media 
with 10-25 uM heme or BLH for 3 hours. Cells were then pelleted in a 1.5 mL centrifuge 
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tube. The cell pellet was then lysed into 100 uL lysis buffer (10mM NaPi, 50mM NaCl, 
5mM EDTA, 0.1% Triton x-100, pH 7.4) with 1x ProteaseArrest and 1 mM 
phenylmethylsulfonyl fluoride with about 1 pellet volume of ZrO beads with a bullet 
blender at speed 8 for 3 minutes at 4⁰C. Cell debris was then removed by centrifuging at  
14 G at 4⁰C and protein concentrations were calculated by Bradford assay. Lysates were 
then diluted to 1 mg/mL protein concentration in 700 uL. 10 uL of streptavidin (20 mg/mL 
stock in PBS stored at 4⁰C) was then added and left at room temperature for 30 minutes. 
Then 10 uL of 1.8 mM biotin in ethanol (stored at 4⁰C) was added and left at room 
temperature for 30 minutes. The samples were then split into 360 uL aliquots. One aliquot 
was treated with 7.2 uL of phosphine-PEG3-biotin (10 mM in DMSO), while the other was 
treated with 7.2 uL DMSO. 240 uL of Sepharose® 4B bead slurry were then washed 3x 
with 400 uL lysis buffer for 10 seconds at 0.1 G. Both lysates were then incubated with the 
240 uL of sepharose® 4B bead slurry at 37⁰C for 3 hours. sepharose® 4B beads were then 
removed and lysates were run through PD SpinTrap™ G-25 Columns following 
recommended protocol to remove excess phosphine-PEG3-biotin and biotin. 50 uL of 
streptavidin magnetic sepharose bead slurry were equilibrated with 200-300 uL of lysis 
buffer. Samples were then incubated with the 50 uL of streptavidin magnetic sepharose 
bead slurry for 30 minutes. Flow through was saved as loading control. Beads were 
collected and washed 3 times with 750 uL lysis buffer for 5 minutes per wash while 
agitating on nutating mixer. 50 uL of 1x SDS (5x SDS diluted into lysis buffer) was then 
added to beads and heated to 100⁰C for 5 minutes to elute protein. In some cases, an 
imidazole elution was done by adding 50 uL of 1 M imidazole in lysis buffer (10mM NaPi, 
50mM NaCl, 5mM EDTA, 0.1% Triton x-100, pH 7.4 after imidazole addition) and 
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incubating for 15 minutes at room temperature. 5x SDS was then added to imidazole eluted 
samples and denatured at 100⁰C for 5 minutes.  Eluents were then run on SDS PAGE and 
stained with Sypro ruby protein stain.   
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